Value of p53 and estrogen receptors immunohistochemical staining in endometrial carcinoma

Dejan Opric, Amer Suskic, Sanela Halilovic Suskic, Gorana Nikolic, Isidora Filipovic


Background: Since there are many articles dealing with estimating prognostic and diagnostic value of ER and p53, using different, usually complex ICH interpretation methods, we wanted to evaluate significance of p53 and ER ICH positivity in endometrial carcinoma, using easily applicable criteria that would help pathologists and clinicians to be sure in ICH findings noted in the report.

Methods: This paper deals with data of the patients treated for endometrial carcinoma in Public Hospitals in Travnik, gynecological department in the period from 1st January 2013 to 1st January 2019. The study included 97 women with endometrial carcinoma, with ages ranging from 42 to 90 years (mean of 64 years). Sample consisted of 72 cases (74.2%) of endometrioid and 25 cases (25.8%) of non-endometrioid carcinoma.

Results: p53 expression was observed in 13.8% carcinomas of the endometrioid type and in 68% carcinomas of non-endometrioid type, while estrogen receptors were more frequently observed in tumors of the endometrioid type (61%) in contrast to non-endometrioid type (28%). Among 72 cases, those with grade I expressed estrogen receptors (26 out of 34 cases - 72%) more frequently than those with grades II and III. Frequency of p53 positivity was significantly higher at higher grades (grade I - 5.8%, grade II - 11.5%, grade III - 71.4%). Stage I carcinomas showed p53 staining less frequently (22.2%) that carcinomas diagnosed at later stages (31.5%).

Conclusions: Using 80% nuclei stained as threshold for p53 positivity, we concluded that p53 is marker of high-grade endometrial carcinomas: high grade endometrioid and non-endometrioid carcinomas. Using 1% of cells as threshold for ER positivity, we confirmed that ER are common in endometrioid type carcinoma, in contrast to non-endometrioid type. Although observed, higher frequency of ER in tumors with lower grade and stage was not statistically confirmed in our study population.


Endometrial carcinoma, Estrogen receptors, Immunohistochemical staining, p53

Full Text:



American Cancer Society. Cancer Facts and Figures 2019. Atlanta: American Cancer Society; 2019 Available at: /dam/cancer-org/research/cancer-facts-and-statistics /annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed on 20th October 2019.

Kurman RJ, Carcangiu ML, Harrington CS, Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press; World Health Organization Classification of Tumors. 4th ed.; 2014:275-278.

Ellenson L, Ronnett BM, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, Ellenson L and Ronnett BM, editors. Blauestein’s Pathology of the Female Genital Tract. 6th edition. New York: Springer-Verlag; 2011:393-452.

Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res. 2005;322:53-61.

Moore KN1, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278-91.

Sherwin R, Catalano R, Sharkey A. Large-scale gene expression studies of the endometrium: what have we learnt? Reprod. 2006;132:1-10.

Shiozawa T, Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis and treatment. The International J Clin Oncol. 2006;11:13-21.

Sankaranarayanan R, Ferley J. Worldwide burden of gynecological cancer: the size of problem. Best Pract Res Clin Obstet Gynecol. 2006;20:207-25.

Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol/Hematol. 2004;50:3-22.

Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 2009;86(10):2083-89.

Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2008;13(4):379-88.

Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol. 2004;93(1):34-40.

Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res. 2005;322:53-61.

Bozdogan O, Atasoy P, Erekul S, Bozdogan N, Bayram M. Apoptosis- related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol. 2008;21:375-82.

Engelsen IB, Akslen LA and Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009;117(10):693-707.

Stavropoulos A, Varras M, Vasilakaki T. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett. 2019;17(5):4575-89.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol. 2019;38 (1):S123-S131.

Debra A. Budwit-Novotny, Kenneth S. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46(10):5419-25.

Heinonen PK, Isola J, Kuoppala T. Immunohistochemical determination of estrogen and progesterone receptors and DNA flow cytometry in endometrial cancer. Int J Gynecol Cancer. 1994;4(3):169-73.

McCarty KS Jr, Miller L, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antire- ceptor antibodies. Arch Pathol Lab Med. 1985;109:716-21.

Goswami S, Sen A, Biswas M. Association of the hormonal receptor status of endometrial carcinomas with the markers of tumor aggression: A comparison with similar studies in developed nations. Med J DY Patil Univ. 2017;10:334-8.

Waqar S, Khan SA, Sarfraz T, Waqar S. Expression of estrogen receptors (ER), progesterone receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor. Pak J Med Sci. 2018;34(2):266-71.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72.

Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008:108(3-5):221-9.

Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res. 2005;11(17):6133-8.

Bockman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-7.

Felix AS, Weissfeld JL, Stone RA. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Cont. 2010;21(11):1851-6.

Esteller M, Xercavins J, Reventos J. Advances in the molecular genetics of endometrial cancer. Oncol Rep. 1999;6:1377-82.

Uharcek P. Prognostic factors in endometrial carcinoma. J Obstat Gynaecol Res. 2008;34(5):776-83.